Established in 1993 and headquartered in Teltow, Germany, co.don AG operates as a global biopharmaceutical firm dedicated to the research, development, and marketing of cell-based pharmaceutical solutions. The company's core focus is on joint preservation and the regenerative repair of articular cartilage defects. Its offerings include Spherox, an advanced three-dimensional chondrocyte product specifically designed to address cartilage damage in adult knee joints. Additionally, co.don AG provides co.don chondrosphere, a therapy utilized for treating cartilage imperfections in younger patients across multiple joints, such as the hip, ankle, shoulder, elbow, and knees. These specialized treatments are primarily employed by orthopedic and trauma surgeons.